Ortec International Inc. (ORTN.OB) And HAPTO Biotech Ltd. Announce Positive Results With Biologically Active Biomaterial Applicable To Cosmetic Tissue Augmentation And Wound Healing Markets 
10/19/2005 5:09:51 PM

NEW YORK--(BUSINESS WIRE)--May 23, 2005--Ortec International, Inc. (ORTN) and HAPTO Biotech, Inc. (HAPTO) announced positive pre-clinical in vivo results generated through their joint venture. The joint venture was established to combine Ortec's and HAPTO's respective technologies to develop a non cellular biologically active enhanced collagen biomaterial to promote the attraction and attachment of healthy cells for application to the wound healing, reconstructive, cosmetic, orthopedic, tissue regeneration and dental markets. The results of the animal study, which are expected to be published shortly, showed that Ortec's proprietary collagen sponge scaffold, modified by attachment of HAPTO's proprietary peptides ("Haptides") that promote cell adhesion, had a higher cell binding potential than standard, untreated collagen. A histological analysis of sub-dermal implants of modified collagen discs in rats indicated that at day 8, collagen sponges treated with the Haptides exhibited greater stability, attracted more skin fibroblasts (30% greater), and resulted in enhanced new collagen deposition with reduced inflammatory reaction when compared to the standard collagen implant control.